📗 Cite This Artifact
CSF and Blood Biomarkers in Progressive Supranuclear Palsy
Cerebrospinal fluid (CSF) and blood-based biomarkers represent minimally invasive approaches for diagnosis, differential diagnosis, and disease monitoring in progressive supranuclear palsy (PSP). These biomarkers reflect the underlying neuropathological processes including tau pathology, neurodegeneration, and neuroinflammation.
Overview of Fluid Biomarkers
Fluid biomarkers in PSP can be categorized into several groups:
| Category | Source | Key Analytes |
|----------|--------|--------------|
| Tau-related | CSF, Blood | Total tau, phosphorylated tau, tau fragments |
| Neurodegeneration | CSF, Blood | NfL, NSE, UCH-L1 |
| Neuroinflammation | CSF, Blood | IL-6, TNF-α, YKL-40 |
| Iron metabolism | CSF, Blood | Ferritin, hepcidin |
| Lipid metabolism | CSF | Apolipoprotein E |
Cerebrospinal Fluid Biomarkers
Tau Proteins in CSF
Total Tau (t-tau)
Total tau reflects neuronal damage and axonal degeneration:
- Elevated levels in PSP compared to healthy controls[@noguchishinohara2019]
- Correlates with disease severity and progression[@hall2022]
- Higher levels in PSP-RS compared to PSP-P variants
- Distinguishes PSP from Parkinson's disease
Phosphorylated Tau (p-tau)
Phosphorylated tau at specific epitopes provides disease-specific information:
- p-tau181: Elevated in PSP vs. PD, but lower than AD[@hampel2023]
- p-tau217: Higher sensitivity for 4R-tauopathies like PSP
- p-tau231: Correlates with disease duration
- The 4R-tau isoforms predominate in PSP, affecting p-tau patterns
Tau Fragments and Tau Oligomers
...
Cerebrospinal fluid (CSF) and blood-based biomarkers represent minimally invasive approaches for diagnosis, differential diagnosis, and disease monitoring in progressive supranuclear palsy (PSP). These biomarkers reflect the underlying neuropathological processes including tau pathology, neurodegeneration, and neuroinflammation.
Overview of Fluid Biomarkers
Fluid biomarkers in PSP can be categorized into several groups:
| Category | Source | Key Analytes |
|----------|--------|--------------|
| Tau-related | CSF, Blood | Total tau, phosphorylated tau, tau fragments |
| Neurodegeneration | CSF, Blood | NfL, NSE, UCH-L1 |
| Neuroinflammation | CSF, Blood | IL-6, TNF-α, YKL-40 |
| Iron metabolism | CSF, Blood | Ferritin, hepcidin |
| Lipid metabolism | CSF | Apolipoprotein E |
Cerebrospinal Fluid Biomarkers
Tau Proteins in CSF
Total Tau (t-tau)
Total tau reflects neuronal damage and axonal degeneration:
- Elevated levels in PSP compared to healthy controls[@noguchishinohara2019]
- Correlates with disease severity and progression[@hall2022]
- Higher levels in PSP-RS compared to PSP-P variants
- Distinguishes PSP from Parkinson's disease
Phosphorylated Tau (p-tau)
Phosphorylated tau at specific epitopes provides disease-specific information:
- p-tau181: Elevated in PSP vs. PD, but lower than AD[@hampel2023]
- p-tau217: Higher sensitivity for 4R-tauopathies like PSP
- p-tau231: Correlates with disease duration
- The 4R-tau isoforms predominate in PSP, affecting p-tau patterns
Tau Fragments and Tau Oligomers
- Tau fragments: C-terminal fragments elevated in PSP CSF
- Tau oligomers: Emerging biomarker with high specificity
- Correlate with tau aggregate load in brain
Neurodegeneration Markers
Neurofilament Light Chain (NfL)
NfL is a marker of axonal damage:
- Markedly elevated in PSP CSF compared to controls[@boxer2020]
- Higher than in Parkinson's disease but lower than in ALS
- Correlates with disease progression rate
- Predicts clinical deterioration
- Useful for disease monitoring in clinical trials
Phosphorylated Neurofilament Heavy Chain (pNfH)
pNfH is a more specific marker for large-caliber myelinated axon damage:
- Elevated in PSP CSF compared to healthy controls
- Higher levels in PSP-RS vs. PSP-P variants
- Good specificity for distinguishing PSP from PD (75-85%)
- Correlates with disease severity and progression
- Complementary to NfL — using both improves diagnostic accuracy
- Annual increase in pNfH correlates with clinical deterioration
- Rate of change predicts progression velocity
- Combined pNfH + NfL monitoring provides comprehensive axonal health assessment
- pNfH serves as pharmacodynamic biomarker in PSP clinical trials
- Baseline to 6-month changes predict treatment response
- Stabilization of pNfH trajectory suggests disease modification
- Used as secondary endpoint in tau-directed therapy trials
See [pNfH Biomarker](/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh) for detailed information.
Neuron-Specific Enolase (NSE)
- Elevated in PSP CSF[@jimnezjimnez2018]
- Reflects neuronal loss
- Correlates with cognitive impairment
Ubiquitin C-Terminal Hydrolase L1 (UCH-L1)
- Elevated in PSP CSF
- Associated with neurodegeneration
- May distinguish PSP from other parkinsonian syndromes
Neuroinflammation Markers
Interleukin-6 (IL-6)
- Elevated in PSP CSF[@lindqvist2020]
- Correlates with disease severity
- Reflects ongoing neuroinflammatory processes
Tumor Necrosis Factor-alpha (TNF-α)
- Increased levels in PSP CSF
- Associated with disease progression
- Therapeutic target potential
YKL-40 (Chitinase-3-Like Protein 1)
- Elevated in PSP CSF[@huang2021]
- Marker of microglial activation
- Correlates with disease duration
Glial Fibrillary Acidic Protein (GFAP)
- Astrocytic marker
- Elevated in PSP
- Reflects astrocytic pathology
Iron Metabolism Markers
Ferritin
- Elevated in PSP CSF[@whitmore2021]
- Reflects iron dysregulation
- Correlates with disease severity
- Related to brain iron accumulation
Hepcidin
- Altered iron metabolism
- Potential biomarker for PSP
Lipid and Membrane Markers
Apolipoprotein E (ApoE)
- ApoE4 associated with faster progression[@formolo2022]
- Influences tau pathology
- Lipid metabolism alterations in PSP
Sphingolipids
- Altered in PSP CSF
- Related to myelin degeneration
Blood-Based Biomarkers
Plasma and Serum Tau
Total Tau (t-tau)
- Elevated in PSP vs. healthy controls
- Similar pattern to CSF but lower sensitivity
- Potential for screening
Phosphorylated Tau (p-tau)
- p-tau181: Elevated in PSP, lower than AD[@janelidze2021]
- p-tau217: Promising for 4R-tauopathies
- Can distinguish PSP from PD
- Emerging use in clinical trials
Tau Fragments
- Various tau fragments detectable in blood
- Disease-specific patterns emerging
Blood Neurofilament Light Chain (NfL)
- Reliably elevated in PSP plasma/serum[@kuhle2020]
- Correlates with CSF NfL
- Excellent for disease monitoring
- Predicts progression
- Used as endpoint in clinical trials
Neuroinflammatory Markers in Blood
IL-6, TNF-α, YKL-40
- Elevated in PSP blood
- Less robust than CSF findings
- Research utility
Blood Iron Markers
- Serum ferritin elevated
- Reflects systemic iron dysregulation
Emerging Blood Biomarkers
Neuronal-Derived Exosomes (NDEs)
- Tau enrichment in neuronal exosomes[@shi2019]
- Specific tau strains in exosomes
- Promising for differential diagnosis
Cell-Free DNA
- Increased levels in PSP
- Potential for early detection
Comparison with Other Biomarker Sources
CSF vs. Blood
| Characteristic | CSF | Blood |
|----------------|-----|-------|
| Sensitivity | Higher | Lower |
| Specificity | Higher | Moderate |
| Invasiveness | Lumipuncture | Blood draw |
| Clinical use | Research | Emerging |
| Biomarker overlap | Substantial | Growing |
Biomarker Panels
Multi-marker panels improve diagnostic accuracy:
- t-tau + NfL + IL-6: High discrimination
- p-tau217 + NfL: Progression prediction
- Tau oligomers + NfL: Disease staging
Clinical Applications
Diagnosis
Fluid biomarkers aid in differential diagnosis:
- PSP vs. PD: NfL, t-tau elevated in PSP
- PSP vs. CBS: Different p-tau patterns
- PSP vs. AD: Lower p-tau181, different p-tau217 patterns
Disease Monitoring
Serial measurements track progression:
- NfL: Annual change correlates with clinical decline
- t-tau: Progression marker
- p-tau: May plateau in later stages
Clinical Trials
Fluid biomarkers serve as:
- Enrollment criteria: Enrich for specific biomarker profiles
- Endpoint measures: NfL as progression marker
- Pharmacodynamic markers: Target engagement indicators
Prognostic Applications
- Baseline NfL predicts progression rate
- p-tau patterns predict phenotype
- Multiple markers improve prognostic accuracy
Methodological Considerations
Preanalytical Factors
- Collection: Standardized lumbar puncture protocol
- Storage: -80°C storage, avoid freeze-thaw cycles
- Timing: Morning collection preferred
Assay Methods
- ELISA: Most common, standardized
- Simoa: Ultra-sensitive for low-abundance proteins
- Mass spectrometry: For precise tau species measurement
- Multiplex: For biomarker panels
Reference Values
- Laboratory-specific cutoffs
- Age-adjusted reference ranges
- Disease-specific thresholds emerging
Integration with Neuroimaging
Fluid biomarkers complement imaging:
- NfL + MRI: Progression assessment
- p-tau + Tau PET: Pathology confirmation
- Multiple markers + DTI: Network degeneration
Future Directions
Technical Developments
- Ultra-sensitive assays improving detection
- Standardization across laboratories
- Point-of-care testing potential
Biomarker Discovery
- Tau strain-specific antibodies
- Single-molecule detection
- Multi-omic approaches
Clinical Implementation
- Validation in large cohorts
- FDA/EMA approval pathways
- Integration into diagnostic criteria
See Also
- [PSP Neuroimaging](/biomarkers/psp-neuroimaging)
- [PSP Disease Progression Staging](/mechanisms/psp-disease-progression-staging)
- [Tau Aggregate Specificity](/mechanisms/psp-tau-aggregate-specificity)
- [Neuroimmune Biomarkers in PSP](/biomarkers/neuroimmune-psp-biomarkers)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [Cortical-Basal Degeneration](/diseases/corticobasal-degeneration)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | biomarkers-psp-fluid-biomarkers |
| kg_node_id | None |
| entity_type | biomarker |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-b3d8db4d58cb |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'biomarkers-psp-fluid-biomarkers'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-biomarkers-psp-fluid-biomarkers?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[CSF and Blood Biomarkers in Progressive Supranuclear Palsy](http://scidex.ai/artifact/wiki-biomarkers-psp-fluid-biomarkers)
http://scidex.ai/artifact/wiki-biomarkers-psp-fluid-biomarkers